GlassScriptPhysician profile
John H Wills
NPI 1457462806
$6,112.98
in general payments reported to CMS, 2019-2025
36 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $917 · 2021: $706 · 2022: $842 · 2023: $1,083 · 2024: $887 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,585.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $732.36 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $380.37 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $377.31 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $314.38 | 2019-2020 | |
| Pfizer INC. | $300.36 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $243.09 | 2022-2023 | Hetlioz, Fanapt |
| Amgen INC. | $235.72 | 2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $228.08 | 2019-2021 | |
| Abbott Laboratories | $177.97 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $174.96 | 2023 | |
| Exact Sciences Corporation | $144.18 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $141.54 | 2021-2024 | Veozah |
| Mylan Specialty L.P. | $125.18 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $120.66 | 2020-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.34 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $102.67 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $84.33 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $53.44 | 2020-2021 | |
| Amarin Pharma, INC. | $51.62 | 2019-2021 | |
| Tris Pharma INC | $51.08 | 2023 | Dyanavel Xr |
| Corium, LLC | $49.31 | 2023-2024 | Azstarys |
| Novartis Pharmaceuticals Corporation | $43.93 | 2019-2022 | |
| Dexcom, INC. | $38.00 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $35.67 | 2019-2020 | |
| Depuy Synthes Sales INC. | $32.86 | 2019-2022 | |
| Viatris Specialty LLC | $30.76 | 2025 | Yupelri |
| Atricure, INC. | $26.07 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $20.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.06 | 2021 | |
| Abbvie INC. | $13.67 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.39 | 2019 | |
| Lupin INC. | $12.14 | 2020 | |
| Hologic Sales and Service, LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.